Overview

Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults

Status:
Not yet recruiting

Trial end date:
2022-11-30

Target enrollment:

Participant gender:

Summary

This randomized trial compares the efficacy of switching to a fixed-dose combination of B/F/TAF versus continuing a boosted protease inhibitor (bPI) regimen in HIV-1 infected participants who are virologically suppressed (HIV-1 RNA <200 copies) on a second-line bPI regimen. Half of participants will receive B/F/TAF and half will continue a bPI regimen. The hypothesize is that B/F/TAF will have efficacy that is non-inferior to the boosted PI regimen.

Phase:

Phase 4

Details

Lead Sponsor:

Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic

Collaborators:

Analysis Group, Inc.
Brigham and Women's Hospital
Harvard Medical School
Harvard Medical School (HMS and HSDM)
Weill Medical College of Cornell University

Treatments:

Emtricitabine
HIV Protease Inhibitors
Protease Inhibitors
Tenofovir